[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-001", "question": "A 71-year-old woman with a dual-chamber pacemaker (DDDR) for sick sinus syndrome presents with episodic dizziness and syncope. Device interrogation reveals normal lead parameters but frequent pacemaker-mediated tachycardia (PMT) episodes terminated by the device's algorithm. However, she continues to report symptoms. Telemetry shows intermittent 2:1 AV block during atrial tracking, with every second P wave falling within post-ventricular atrial refractory period (PVARP). Which programming adjustment will most effectively eliminate symptoms while preserving maximal atrioventricular synchrony?", "options": ["Extend PVARP by 50 ms", "Enable dynamic PVARP extension after premature ventricular contractions", "Reduce upper tracking limit to 120 bpm", "Switch to DDI mode at rest", "Enable atrial preference pacing"], "answer": "B", "answer_index": 1, "explanation": "Dynamic PVARP extension after PVCs prevents retrograde conduction from initiating PMT while preserving atrial tracking during sinus rhythm. Extending PVARP statically (A) would worsen 2:1 block and cause pacemaker syndrome. Reducing upper tracking (C) does not prevent PMT initiation. DDI mode (D) eliminates atrial tracking entirely. Atrial preference pacing (E) is irrelevant to PMT prevention.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible due to stem–key mismatch)\\nVerdict on keyed answer: Miskeyed – option B is not the best answer given the stem’s stated problem.\\nKey stem clues: Symptoms (dizziness/syncope) persist despite PMT episodes already being detected and terminated by the device’s algorithm. Telemetry highlights intermittent 2:1 AV block during atrial tracking with every second P wave falling in PVARP. The explicit hemodynamic issue is loss of AV synchrony from functional 2:1 block, not ongoing PMT.\\nThe question asks for a programming change to eliminate symptoms while preserving maximal AV synchrony. The direct cause of symptoms, as written, is the 2:1 tracking related to PVARP timing. Among listed options, static PVARP extension (A) is indeed wrong (worsens 2:1), and B (dynamic PVARP after PVCs) is standard for preventing PMT but doesn’t address the described 2:1 block, which is not PVC-triggered in the stem. No option clearly resolves the 2:1 block while preserving DDDR tracking; thus PMT prevention (B) doesn’t logically solve the described symptomatic mechanism.\\nMain medical accuracy issue: Explanation focuses on PMT prevention while the stem’s symptomatic problem is 2:1 tracking from PVARP.\\nMinimal fix: Reframe stem to emphasize recurrent symptomatic PMT after PVCs without mentioning symptomatic 2:1 AV block, or change options to include a PVARP shortening/AV-delay modification that corrects 2:1 tracking.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible due to stem–key mismatch)\nVerdict on keyed answer: Miskeyed – option B is not the best answer given the stem’s stated problem.\nKey stem clues: Symptoms (dizziness/syncope) persist despite PMT episodes already being detected and terminated by the device’s algorithm. Telemetry highlights intermittent 2:1 AV block during atrial tracking with every second P wave falling in PVARP. The explicit hemodynamic issue is loss of AV synchrony from functional 2:1 block, not ongoing PMT.\nThe question asks for a programming change to eliminate symptoms while preserving maximal AV synchrony. The direct cause of symptoms, as written, is the 2:1 tracking related to PVARP timing. Among listed options, static PVARP extension (A) is indeed wrong (worsens 2:1), and B (dynamic PVARP after PVCs) is standard for preventing PMT but doesn’t address the described 2:1 block, which is not PVC-triggered in the stem. No option clearly resolves the 2:1 block while preserving DDDR tracking; thus PMT prevention (B) doesn’t logically solve the described symptomatic mechanism.\nMain medical accuracy issue: Explanation focuses on PMT prevention while the stem’s symptomatic problem is 2:1 tracking from PVARP.\nMinimal fix: Reframe stem to emphasize recurrent symptomatic PMT after PVCs without mentioning symptomatic 2:1 AV block, or change options to include a PVARP shortening/AV-delay modification that corrects 2:1 tracking.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-002", "question": "A 42-year-old man with a heterozygous CSF1R p.Arg782His mutation and early-stage adult-onset leukoencephalopathy with axonal spheroids (ALSP) has mild cognitive impairment and gait instability. His sister progressed to severe dementia within 3 years of symptom onset. Which intervention has demonstrated the highest disease-modifying efficacy when performed before onset of severe motor disability?", "options": ["Intravenous immunoglobulin monthly", "Oral cyclophosphamide 2 mg/kg/day", "Allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor", "Ruxolitinib 20 mg twice daily", "Supportive care with donepezil"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic HSCT is the only intervention shown to halt ALSP progression when performed early, before severe disability, by replacing microglial precursors. IVIG (A) and cyclophosphamide (B) lack efficacy. Ruxolitinib (D) has no clinical data. Supportive care (E) does not modify disease course. Delay until severe motor impairment predicts transplant failure.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Genetically confirmed CSF1R-related ALSP, early-stage symptoms (mild cognitive impairment, gait instability), family history of rapid progression, and question asking for the intervention with the highest *disease-modifying* efficacy when done before severe motor disability. Current literature reports allogeneic hematopoietic stem cell transplantation (HSCT) as the only intervention with demonstrated potential to halt or markedly slow progression in CSF1R-ALSP when performed early, via donor-derived microglial engraftment.\\nOption analysis: C fits pathophysiology and available case-series data and specifically matches the timing criterion (“before onset of severe motor disability”). A (IVIG) and B (cyclophosphamide) have no evidence of benefit in ALSP and would not be expected to help a primary microglial/leukoencephalopathy. D (ruxolitinib) has no supporting clinical data in ALSP. E (donepezil) is purely symptomatic, not disease-modifying.\\nMain medical accuracy issues: Very rare-disease, low-evidence (case series) area but correctly reflects current best-available data and expert opinion.\\nMinimal fix: Explicitly state “Based on current clinical reports and case series…” in the explanation (not the stem) to clarify the evidence level without changing the keyed answer.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Genetically confirmed CSF1R-related ALSP, early-stage symptoms (mild cognitive impairment, gait instability), family history of rapid progression, and question asking for the intervention with the highest *disease-modifying* efficacy when done before severe motor disability. Current literature reports allogeneic hematopoietic stem cell transplantation (HSCT) as the only intervention with demonstrated potential to halt or markedly slow progression in CSF1R-ALSP when performed early, via donor-derived microglial engraftment.\nOption analysis: C fits pathophysiology and available case-series data and specifically matches the timing criterion (“before onset of severe motor disability”). A (IVIG) and B (cyclophosphamide) have no evidence of benefit in ALSP and would not be expected to help a primary microglial/leukoencephalopathy. D (ruxolitinib) has no supporting clinical data in ALSP. E (donepezil) is purely symptomatic, not disease-modifying.\nMain medical accuracy issues: Very rare-disease, low-evidence (case series) area but correctly reflects current best-available data and expert opinion.\nMinimal fix: Explicitly state “Based on current clinical reports and case series…” in the explanation (not the stem) to clarify the evidence level without changing the keyed answer.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-003", "question": "A 64-year-old man with metastatic hemangiopericytoma presents with refractory hypoglycemia (glucose 28 mg/dL) despite 20% dextrose infusion at 100 mL/hour. Labs show insulin <2 μIU/mL, C-peptide 0.1 ng/mL, IGF-2 850 ng/mL (normal 50-200), and IGF-2:IGF-1 ratio 12:1. Which immediate pharmacologic intervention is most likely to achieve euglycemia within 24 hours?", "options": ["Continuous hydrocortisone infusion 10 mg/hour", "Recombinant IGF-1 40 mg subcutaneously twice daily", "Diazoxide 300 mg orally three times daily", "Octreotide 200 μg subcutaneously three times daily", "Glucagon 2 mg intramuscularly every 4 hours"], "answer": "A", "answer_index": 0, "explanation": "High-dose glucocorticoids suppress aberrant IGF-2 production from the tumor, correcting hypoglycemia within hours. Recombinant IGF-1 (B) worsens the IGF-2:IGF-1 imbalance. Diazoxide (C) and octreotide (D) are ineffective in non-islet cell tumor hypoglycemia due to suppressed insulin. Glucagon (E) provides only transient effect and cannot sustain normoglycemia.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Metastatic hemangiopericytoma, severe refractory hypoglycemia despite concentrated dextrose; very low insulin and C‑peptide; markedly elevated IGF‑2 and high IGF‑2:IGF‑1 ratio → classic non–islet cell tumor hypoglycemia (NICTH) due to IGF‑2 overproduction. The question asks for an *immediate pharmacologic intervention* likely to normalize glucose within 24 h.\\nHigh‑dose glucocorticoids are standard first‑line medical therapy in NICTH: they reduce tumor IGF‑2 production and increase gluconeogenesis, often correcting hypoglycemia within hours to a day. A continuous hydrocortisone infusion at 10 mg/h (240 mg/day) is a high‑dose regimen and is the only option addressing the mechanism and providing sustained effect.\\nOption B (recombinant IGF‑1) would aggravate hypoglycemia. C (diazoxide) and D (octreotide) target insulin secretion, which is already suppressed, so they are mechanistically inappropriate. E (repeated glucagon IM) can transiently raise glucose but is unlikely to reliably maintain euglycemia over 24 h, especially in a critically ill, likely glycogen‑depleted patient.\\nMain medical issues: Dosing and timeframe are reasonable; explanation consistent with current understanding. Minimal fix: Clarify \\\"high‑dose intravenous glucocorticoids (e.g., hydrocortisone 200–300 mg/day)\\\" in option A to make intent explicit.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Metastatic hemangiopericytoma, severe refractory hypoglycemia despite concentrated dextrose; very low insulin and C‑peptide; markedly elevated IGF‑2 and high IGF‑2:IGF‑1 ratio → classic non–islet cell tumor hypoglycemia (NICTH) due to IGF‑2 overproduction. The question asks for an *immediate pharmacologic intervention* likely to normalize glucose within 24 h.\nHigh‑dose glucocorticoids are standard first‑line medical therapy in NICTH: they reduce tumor IGF‑2 production and increase gluconeogenesis, often correcting hypoglycemia within hours to a day. A continuous hydrocortisone infusion at 10 mg/h (240 mg/day) is a high‑dose regimen and is the only option addressing the mechanism and providing sustained effect.\nOption B (recombinant IGF‑1) would aggravate hypoglycemia. C (diazoxide) and D (octreotide) target insulin secretion, which is already suppressed, so they are mechanistically inappropriate. E (repeated glucagon IM) can transiently raise glucose but is unlikely to reliably maintain euglycemia over 24 h, especially in a critically ill, likely glycogen‑depleted patient.\nMain medical issues: Dosing and timeframe are reasonable; explanation consistent with current understanding. Minimal fix: Clarify \"high‑dose intravenous glucocorticoids (e.g., hydrocortisone 200–300 mg/day)\" in option A to make intent explicit.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-004", "question": "A 59-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and weight loss. HRCT demonstrates upper lobe-predominant pleural thickening, subpleural consolidation, and traction bronchiectasis with severe volume loss. Surgical lung biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation, extending into the pleura. Which histopathologic finding most strongly differentiates this from usual interstitial pneumonia?", "options": ["Fibroblast foci within alveolar walls", "Honeycomb change with mucin-filled cysts", "Presence of intra-alveolar fibroblastic plugs", "Elastosis involving visceral pleura and subpleural parenchyma", "Patchy temporally heterogeneous fibrosis"], "answer": "D", "answer_index": 3, "explanation": "Pleuroparenchymal fibroelastosis (PPFE) is defined by characteristic elastosis of both pleura and subpleural parenchyma, which is absent in UIP. Fibroblast foci (A) and honeycomb change (B) are hallmark UIP features. Intra-alveolar fibroblastic plugs (C) suggest organizing pneumonia. Patchy heterogeneous fibrosis (E) is typical of UIP, whereas PPFE shows uniform elastotic fibrosis.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: RA patient on methotrexate with progressive dyspnea, HRCT showing upper lobe–predominant pleural thickening, subpleural consolidation, traction bronchiectasis with severe volume loss, and biopsy demonstrating dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation extending into the pleura. This constellation describes pleuroparenchymal fibroelastosis (PPFE), not usual interstitial pneumonia (UIP). The question asks which histologic feature most strongly differentiates PPFE from UIP. \\nOption D (elastosis involving visceral pleura and subpleural parenchyma) is the defining feature of PPFE and is not a feature of UIP, so it is the uniquely correct answer. Options A, B, and E list hallmark findings of UIP; option C describes organizing pneumonia, not a UIP–PPFE discriminator. Thus only D fits both the described case and the requested discriminator.\\nMain logical issues: None—stem is coherent and adequately specified; choices are clearly distinguishable.\\nMain medical accuracy issues: None; pathologic descriptions of UIP, PPFE, and organizing pneumonia are accurate and contemporary.\\nMinimal fix: Add the explicit diagnostic label “consistent with pleuroparenchymal fibroelastosis” to the biopsy description to make the teaching point even more transparent, though it is not required for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: RA patient on methotrexate with progressive dyspnea, HRCT showing upper lobe–predominant pleural thickening, subpleural consolidation, traction bronchiectasis with severe volume loss, and biopsy demonstrating dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation extending into the pleura. This constellation describes pleuroparenchymal fibroelastosis (PPFE), not usual interstitial pneumonia (UIP). The question asks which histologic feature most strongly differentiates PPFE from UIP. \nOption D (elastosis involving visceral pleura and subpleural parenchyma) is the defining feature of PPFE and is not a feature of UIP, so it is the uniquely correct answer. Options A, B, and E list hallmark findings of UIP; option C describes organizing pneumonia, not a UIP–PPFE discriminator. Thus only D fits both the described case and the requested discriminator.\nMain logical issues: None—stem is coherent and adequately specified; choices are clearly distinguishable.\nMain medical accuracy issues: None; pathologic descriptions of UIP, PPFE, and organizing pneumonia are accurate and contemporary.\nMinimal fix: Add the explicit diagnostic label “consistent with pleuroparenchymal fibroelastosis” to the biopsy description to make the teaching point even more transparent, though it is not required for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-005", "question": "A 26-year-old woman ingests 60 mg of colchicine in a suicide attempt, presenting 8 hours later with profuse vomiting and diarrhea. Labs: WBC 22,000/μL, platelets 600,000/μL. Which intervention, when initiated within 12 hours of ingestion, has demonstrated mortality reduction in severe colchicine poisoning?", "options": ["Colchicine-specific Fab fragments 4 g IV bolus", "Granulocyte colony-stimulating factor 5 μg/kg/day subcutaneously", "Continuous venovenous hemofiltration at 50 mL/kg/hour", "N-acetylcysteine 150 mg/kg IV loading dose", "Plasma exchange daily for 5 days"], "answer": "B", "answer_index": 1, "explanation": "Early G-CSF administration reduces mortality by preventing septic complications from bone marrow suppression that begins 24-48 hours post-ingestion. Colchicine Fab (A) is experimental and unavailable. CVVH (C) does not enhance colchicine clearance due to large volume of distribution. NAC (D) has no role. Plasma exchange (E) is ineffective for intracellular toxins.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Massive colchicine overdose (60 mg) in a young adult, early GI phase (profuse vomiting/diarrhea) at 8 hours, high risk of progression to bone marrow suppression and septic complications, question explicitly asks for an intervention that, when initiated within 12 hours, has demonstrated mortality reduction in *severe colchicine poisoning*.\\nG-CSF (B) is supported by case series and toxicology literature as a beneficial early therapy in severe colchicine poisoning, associated with improved survival by mitigating neutropenia and infectious complications; timing within the first 12–24 hours is emphasized. Other options are inferior: (A) Colchicine-specific Fab is experimental/limited-access and not established to reduce mortality; (C) CVVH is ineffective due to colchicine’s large Vd and protein binding; (D) NAC is for acetaminophen and has no established role here; (E) Plasma exchange is not useful for a primarily intracellular toxin.\\nMain logical issue(s): None significant; the stem clearly leads to G-CSF as the only evidence‑based mortality‑reducing adjunct.\\nMain medical accuracy issue(s): Minor—evidence base is limited (case reports/series rather than RCTs), but consistent with toxicology consensus.\\nMinimal fix: Add a phrase like “based on available clinical case-series evidence” to clarify the strength of data for mortality reduction with G-CSF.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Massive colchicine overdose (60 mg) in a young adult, early GI phase (profuse vomiting/diarrhea) at 8 hours, high risk of progression to bone marrow suppression and septic complications, question explicitly asks for an intervention that, when initiated within 12 hours, has demonstrated mortality reduction in *severe colchicine poisoning*.\nG-CSF (B) is supported by case series and toxicology literature as a beneficial early therapy in severe colchicine poisoning, associated with improved survival by mitigating neutropenia and infectious complications; timing within the first 12–24 hours is emphasized. Other options are inferior: (A) Colchicine-specific Fab is experimental/limited-access and not established to reduce mortality; (C) CVVH is ineffective due to colchicine’s large Vd and protein binding; (D) NAC is for acetaminophen and has no established role here; (E) Plasma exchange is not useful for a primarily intracellular toxin.\nMain logical issue(s): None significant; the stem clearly leads to G-CSF as the only evidence‑based mortality‑reducing adjunct.\nMain medical accuracy issue(s): Minor—evidence base is limited (case reports/series rather than RCTs), but consistent with toxicology consensus.\nMinimal fix: Add a phrase like “based on available clinical case-series evidence” to clarify the strength of data for mortality reduction with G-CSF.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-006", "question": "A 55-year-old man with severe Barlow's disease undergoes 3D transesophageal echocardiography for mitral valve repair planning. The surgeon asks you to identify the parameter that best predicts durable repair. Which measurement most strongly correlates with successful leaflet coaptation after annuloplasty?", "options": ["Anterior leaflet length >35 mm", "Posterior leaflet thickness >5 mm", "Annular height to commissural width ratio >0.3", "Flail gap distance <10 mm", "Coaptation depth >15 mm"], "answer": "C", "answer_index": 2, "explanation": "Annular height to commissural width ratio >0.3 indicates adequate leaflet tissue and annular dynamics, predicting successful repair. Excessive leaflet length (A) and thickness (B) increase complexity but do not predict success. Flail gap (D) and coaptation depth (E) are important but secondary to annular geometry in Barlow's disease where tissue redundancy is the primary pathology.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified, potentially M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: severe Barlow’s disease; 3D TEE for repair planning; question asks which measurement “most strongly correlates with successful leaflet coaptation after annuloplasty” and “best predicts durable repair.” In degenerative MR, commonly cited predictors of reparability and durable repair include limited/flail gap and width, adequate coaptation length and depth, and leaflet/annular geometry; however, no single universally accepted parameter clearly dominates across all sources, especially for Barlow’s disease specifically. The keyed answer (annular height to commissural width ratio >0.3) is plausible but not clearly established as superior to flail gap distance or coaptation parameters as the “most strongly correlating” metric. Without a specified evidence base or more context, both C and D (and arguably E) could be defended, so the stem does not support a uniquely best answer. Medical accuracy is generally reasonable but overstates the primacy of AHCWR. Minimal fix: Rephrase stem to reference a specific study/guideline where AHCWR >0.3 is shown as the strongest predictor, or adjust options/wording to “which parameter is classically used in Barlow’s disease to predict durable repair: AHCWR >0.3.”\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified, potentially M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: severe Barlow’s disease; 3D TEE for repair planning; question asks which measurement “most strongly correlates with successful leaflet coaptation after annuloplasty” and “best predicts durable repair.” In degenerative MR, commonly cited predictors of reparability and durable repair include limited/flail gap and width, adequate coaptation length and depth, and leaflet/annular geometry; however, no single universally accepted parameter clearly dominates across all sources, especially for Barlow’s disease specifically. The keyed answer (annular height to commissural width ratio >0.3) is plausible but not clearly established as superior to flail gap distance or coaptation parameters as the “most strongly correlating” metric. Without a specified evidence base or more context, both C and D (and arguably E) could be defended, so the stem does not support a uniquely best answer. Medical accuracy is generally reasonable but overstates the primacy of AHCWR. Minimal fix: Rephrase stem to reference a specific study/guideline where AHCWR >0.3 is shown as the strongest predictor, or adjust options/wording to “which parameter is classically used in Barlow’s disease to predict durable repair: AHCWR >0.3.”", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-007", "question": "A 67-year-old man presents with 18 months of progressive insomnia, dysautonomia, bulbar dysfunction, and gait instability. Polysomnography shows severe sleep fragmentation with complete loss of REM sleep. Anti-IgLON5 antibodies are positive in serum and CSF. Which therapeutic strategy has demonstrated modest symptomatic benefit in this tauopathy-mediated autoimmune disorder?", "options": ["High-dose intravenous methylprednisolone 1 g daily for 5 days", "Plasma exchange every other day for 2 weeks", "Rituximab 1 g IV every 2 weeks for 2 doses", "Combined immunotherapy with steroids, IVIG, and rituximab", "Trazodone 100 mg nightly for sleep restoration"], "answer": "D", "answer_index": 3, "explanation": "Combined immunotherapy offers modest benefit in IgLON5 disease by targeting both autoimmune and inflammatory components, though tauopathy progression continues. Monotherapy with steroids (A), plasma exchange (B), or rituximab (C) alone has shown minimal efficacy. Trazodone (E) cannot restore lost REM sleep architecture in this neurodegenerative disorder.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Older man; 18 months of progressive insomnia, dysautonomia, bulbar dysfunction, gait instability; polysomnography with severe fragmentation and complete loss of REM; serum and CSF anti-IgLON5 antibodies; explicitly identified as a tauopathy-mediated autoimmune disorder; question asks which therapeutic strategy has demonstrated modest symptomatic benefit.\\nBest diagnosis/mechanism: Anti-IgLON5 disease, a neurodegenerative tauopathy with autoimmune features, often poorly responsive to single-agent immunotherapy but with some benefit from combined regimens.\\nWhy D is best: Literature and expert consensus suggest that combined immunotherapy (steroids, IVIG, rituximab and/or other agents) may yield modest symptomatic benefit, whereas monotherapies (steroids, PLEX, or rituximab alone) generally show limited effect. Trazodone cannot reverse loss of REM architecture and does not address the autoimmune component.\\nOther options: A, B, C each represent plausible but generally less effective monotherapies per current reports; E is purely symptomatic for insomnia and not disease-modifying and does not restore REM in this context.\\nMain issues: Item relies on somewhat limited-evidence area but reflects prevailing understanding. Minimal fix: Cite “based on case series and cohort data” in explanation to acknowledge evidence level, without changing stem/choices/key.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Older man; 18 months of progressive insomnia, dysautonomia, bulbar dysfunction, gait instability; polysomnography with severe fragmentation and complete loss of REM; serum and CSF anti-IgLON5 antibodies; explicitly identified as a tauopathy-mediated autoimmune disorder; question asks which therapeutic strategy has demonstrated modest symptomatic benefit.\nBest diagnosis/mechanism: Anti-IgLON5 disease, a neurodegenerative tauopathy with autoimmune features, often poorly responsive to single-agent immunotherapy but with some benefit from combined regimens.\nWhy D is best: Literature and expert consensus suggest that combined immunotherapy (steroids, IVIG, rituximab and/or other agents) may yield modest symptomatic benefit, whereas monotherapies (steroids, PLEX, or rituximab alone) generally show limited effect. Trazodone cannot reverse loss of REM architecture and does not address the autoimmune component.\nOther options: A, B, C each represent plausible but generally less effective monotherapies per current reports; E is purely symptomatic for insomnia and not disease-modifying and does not restore REM in this context.\nMain issues: Item relies on somewhat limited-evidence area but reflects prevailing understanding. Minimal fix: Cite “based on case series and cohort data” in explanation to acknowledge evidence level, without changing stem/choices/key.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-008", "question": "A 28-year-old phenotypic female with 46,XY karyotype and complete androgen insensitivity syndrome (CAIS) due to a null androgen receptor mutation presents with hypertension (BP 165/100 mmHg) and hypokalemia (K+ 2.8 mEq/L). Plasma renin is suppressed (<0.5 ng/mL/hr) and aldosterone is elevated (35 ng/dL). Which pharmacologic agent specifically targets the underlying mineralocorticoid excess in this syndrome?", "options": ["Eplerenone 50 mg twice daily", "Spironolactone 100 mg twice daily", "Amiloride 10 mg twice daily", "Dexamethasone 0.5 mg nightly", "Finasteride 5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "In CAIS, non-aromatized androgens directly activate mineralocorticoid receptors, causing hypertension. Spironolactone (B) antagonizes this effect while also blocking residual androgen receptor activity. Eplerenone (A) is less effective at the androgen-mediated mineralocorticoid effect. Amiloride (C) treats symptoms but not the mechanism. Dexamethasone (D) suppresses ACTH but not peripheral androgen production. Finasteride (E) blocks 5-alpha-reductase, irrelevant in CAIS with absent receptor function.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no defensible answer)\\nVerdict on keyed answer: Miskeyed/biologically implausible; no option clearly matches a real underlying mechanism.\\nKey stem clues: 46,XY CAIS with null androgen receptor; hypertension, hypokalemia; low renin and high aldosterone implying primary hyperaldosteronism; question asks for a drug that “specifically targets the underlying mineralocorticoid excess in this syndrome.” The explanation asserts that “non‑aromatized androgens directly activate mineralocorticoid receptors” in CAIS and that spironolactone uniquely treats this.\\nMain logical issues: In established physiology, CAIS is not a recognized cause of primary hyperaldosteronism, and androgens are not clinically relevant direct mineralocorticoid receptor agonists in this way. The labs are classic for primary aldosteronism (adrenal adenoma/hyperplasia), not for androgen-driven mineralocorticoid excess. The prompt insists the mineralocorticoid excess is intrinsic to CAIS, which is medically inaccurate; thus the best treatment should be an MR antagonist for primary aldosteronism (spironolactone or eplerenone), but the entire framing is incorrect, so no choice is truly “specific to this syndrome.”\\nMain medical accuracy issues: Pathophysiology is wrong and would mislead learners.\\nMinimal fix: Remove the CAIS link and frame as primary hyperaldosteronism; then ask for preferred MR antagonist (e.g., eplerenone vs spironolactone) with an accurate rationale.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no defensible answer)\nVerdict on keyed answer: Miskeyed/biologically implausible; no option clearly matches a real underlying mechanism.\nKey stem clues: 46,XY CAIS with null androgen receptor; hypertension, hypokalemia; low renin and high aldosterone implying primary hyperaldosteronism; question asks for a drug that “specifically targets the underlying mineralocorticoid excess in this syndrome.” The explanation asserts that “non‑aromatized androgens directly activate mineralocorticoid receptors” in CAIS and that spironolactone uniquely treats this.\nMain logical issues: In established physiology, CAIS is not a recognized cause of primary hyperaldosteronism, and androgens are not clinically relevant direct mineralocorticoid receptor agonists in this way. The labs are classic for primary aldosteronism (adrenal adenoma/hyperplasia), not for androgen-driven mineralocorticoid excess. The prompt insists the mineralocorticoid excess is intrinsic to CAIS, which is medically inaccurate; thus the best treatment should be an MR antagonist for primary aldosteronism (spironolactone or eplerenone), but the entire framing is incorrect, so no choice is truly “specific to this syndrome.”\nMain medical accuracy issues: Pathophysiology is wrong and would mislead learners.\nMinimal fix: Remove the CAIS link and frame as primary hyperaldosteronism; then ask for preferred MR antagonist (e.g., eplerenone vs spironolactone) with an accurate rationale.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Systemic sclerosis with severe pre-capillary pulmonary hypertension (mPAP 52, PAWP 6, PVR 11), lung biopsy showing diffuse capillary proliferation in alveolar septa without atypia → classic for pulmonary capillary hemangiomatosis, a rare WHO Group 1’ pulmonary hypertension subtype. Clinical note that she has failed epoprostenol and macitentan indicates refractoriness to standard PAH therapy. Question explicitly asks for the intervention associated with greatest 5‑year survival in this subset.\\nEvaluation: PCH is known to respond poorly or worsen with PAH vasodilators; immunosuppression is not effective; balloon pulmonary angioplasty is indicated for chronic thromboembolic PH (Group 4) and is contraindicated in diffuse microvascular diseases like PCH due to risk of hemorrhage. Bilateral lung transplantation is accepted as the only intervention with meaningful survival benefit in advanced PCH.\\nMain medical issues: Content and associations are consistent with current understanding of PCH; survival figures are plausible, though data are limited due to rarity.\\nMinimal fix: Clarify in stem that high‑resolution CT shows findings consistent with PCH to avoid any ambiguity with other capillary proliferative or veno‑occlusive processes.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Systemic sclerosis with severe pre-capillary pulmonary hypertension (mPAP 52, PAWP 6, PVR 11), lung biopsy showing diffuse capillary proliferation in alveolar septa without atypia → classic for pulmonary capillary hemangiomatosis, a rare WHO Group 1’ pulmonary hypertension subtype. Clinical note that she has failed epoprostenol and macitentan indicates refractoriness to standard PAH therapy. Question explicitly asks for the intervention associated with greatest 5‑year survival in this subset.\nEvaluation: PCH is known to respond poorly or worsen with PAH vasodilators; immunosuppression is not effective; balloon pulmonary angioplasty is indicated for chronic thromboembolic PH (Group 4) and is contraindicated in diffuse microvascular diseases like PCH due to risk of hemorrhage. Bilateral lung transplantation is accepted as the only intervention with meaningful survival benefit in advanced PCH.\nMain medical issues: Content and associations are consistent with current understanding of PCH; survival figures are plausible, though data are limited due to rarity.\nMinimal fix: Clarify in stem that high‑resolution CT shows findings consistent with PCH to avoid any ambiguity with other capillary proliferative or veno‑occlusive processes.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-010", "question": "A 62-year-old man with chronic type B aortic dissection (diagnosed 3 years ago) presents with massive hemoptysis. CT angiography shows a 7 cm ulcer-like projection in the descending thoracic aorta with active contrast extravasation into the left lower lobe bronchus. He is hypotensive (BP 85/50 mmHg). Which immediate management strategy has the lowest mortality in this aortobronchial fistula complication?", "options": ["Emergent thoracotomy with open surgical repair", "Thoracic endovascular aortic repair (TEVAR) with left subclavian coverage", "TEVAR with adjunctive left subclavian artery revascularization", "Balloon tamponade of the aortic true lumen", "Massive transfusion protocol only"], "answer": "C", "answer_index": 2, "explanation": "Aortobronchial fistula requires emergent TEVAR to seal the rupture. Adjunctive left subclavian revascularization (C) prevents spinal ischemia and reduces perioperative stroke risk compared to coverage alone (B). Open repair (A) carries >80% mortality in this setting. Balloon tamponade (D) is a temporary bridge only. Transfusion alone (E) is futile without definitive hemorrhage control.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Chronic type B dissection, now with massive hemoptysis, CTA showing ulcer-like projection with active contrast extravasation into the bronchial tree (aortobronchial fistula), patient hypotensive. The question explicitly asks for the immediate management strategy associated with the lowest mortality in this complication.\\nTEVAR is now standard first-line for rupturing/complicated descending thoracic aortic pathology including aortobronchial fistula, with substantially lower mortality than emergent open thoracotomy/repair (A). Between B and C, covering the left subclavian is often necessary to obtain an adequate proximal landing zone; when feasible in a non-arrest setting, adjunctive left subclavian revascularization (C) is associated with lower rates of spinal cord ischemia and stroke versus coverage alone (B), making C the best overall strategy for minimizing mortality/morbidity.\\nD (balloon tamponade) is a bridge maneuver, not definitive; E (transfusion alone) is inappropriate without hemorrhage control.\\nMain medical accuracy issues: Minor nuance—some centers may defer revascularization in crashing patients, but as a general “best strategy” for lowest mortality, C is defensible.\\nMinimal fix: Explicitly state he is being managed in a center with immediate endovascular and vascular surgery capability to reinforce C as best choice.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Chronic type B dissection, now with massive hemoptysis, CTA showing ulcer-like projection with active contrast extravasation into the bronchial tree (aortobronchial fistula), patient hypotensive. The question explicitly asks for the immediate management strategy associated with the lowest mortality in this complication.\nTEVAR is now standard first-line for rupturing/complicated descending thoracic aortic pathology including aortobronchial fistula, with substantially lower mortality than emergent open thoracotomy/repair (A). Between B and C, covering the left subclavian is often necessary to obtain an adequate proximal landing zone; when feasible in a non-arrest setting, adjunctive left subclavian revascularization (C) is associated with lower rates of spinal cord ischemia and stroke versus coverage alone (B), making C the best overall strategy for minimizing mortality/morbidity.\nD (balloon tamponade) is a bridge maneuver, not definitive; E (transfusion alone) is inappropriate without hemorrhage control.\nMain medical accuracy issues: Minor nuance—some centers may defer revascularization in crashing patients, but as a general “best strategy” for lowest mortality, C is defensible.\nMinimal fix: Explicitly state he is being managed in a center with immediate endovascular and vascular surgery capability to reinforce C as best choice.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]